Also trades as: CTCXW (NASDAQ) · $vol 0M
CTCX NASDAQ
Carmell Therapeutics Corporation
1W: -4.9%
1M: -39.9%
3M: -83.1%
1Y: -95.5%
3Y: -98.8%
$0.20
Last traded 2025-04-04 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$5.9M
52W Range0.1701-3
Volume63,382
Avg Volume8,105,553
Beta0.51
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORajiv Sarman Shukla
Employees9
SectorHealthcare
IndustryBiotechnology
IPO Date2021-09-23
Websitecarmellrx.com
2403 Sidney Street
Pittsburgh, PA 15203
US
Pittsburgh, PA 15203
US
412 894 8248
About Carmell Therapeutics Corporation
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Anderson David W | P-Purchase | 739 | $3.94 | 2023-12-15 |
| Anderson David W | P-Purchase | 391 | $3.61 | 2023-12-14 |
| Anderson David W | P-Purchase | 1,087 | $5.57 | 2023-12-13 |
| Anderson David W | P-Purchase | 1,087 | $3.50 | 2023-12-12 |
| Anderson David W | P-Purchase | 1,087 | $3.53 | 2023-12-11 |